MNKD Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas

03

Preço $3.80

Capitalização de Mercado (MRQ) $1.18B

P/E (TTM) -29.2

EPS (TTM) $-0.13

Receita (TTM) $394M

ROE (TTM) 71.4%

Intervalo 52 Semanas $2–$7

MNKD Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização

04

intervalo

barras

A granularidade da barra se adapta ao período selecionado — passe o mouse sobre o gráfico para ver a abertura/máxima/mínima/fechamento de uma barra.

Divisões de Ações 1

Data ex	Desdobramento	Tipo
3 de Março de 2017	1-for-5	Reverso

Sobre MannKind Corporation - Common Stock Visão geral da empresa da Wikipedia

05 · wikidata

MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.

MannKind Corporation was named after its founder, Alfred E. Mann.

History

Founded in February 1991, the company's present form is a result of a 2003 merger of three companies owned by Alfred E. Mann: Pharmaceutical Discovery Corporation (PDC), the cancer vaccine developer CTL ImmunoTherapies, Inc., and its sister company Allecure Corp, which was developing an allergy vaccine technology. Pharmaceutical Discovery was purchased in 2001 from Solomon Steiner; with that purchase MannKind acquired the Technosphere molecule and Medtone inhaler, upon which was developed its lead product, Afrezza (inhalable insulin).

The FDA approved Afrezza on June 27, 2014.

On August 11, 2014 MannKind entered into an exclusive global licensing agreement with Sanofi for Afrezza sales. Under the agreement, MannKind received $150 million cash from Sanofi, in exchange for sharing profits and losses of sales of Afrezza, with 65% for Sanofi and 35% for MannKind. On January 5, 2016, MannKind Corporation announced the termination of the license and collaboration agreement with Sanofi. By December 2017, the company had lost 11% of its trading volume due to the poor sales.

In March 2020, the company announced it was working with fellow pharmaceutical company Immix Biopharma to try to develop an inhalable treatment for acute respiratory distress syndrome, a lung disease.

Products and product candidates

The firm has developed Afrezza a rapid-acting insulin peaking 12 to 15 minutes after inhalation and exiting the body within 2–3 hours. The inhalation technology uses a miniature, breath-powered inhaler in combination with single-use cartridges containing pre-metered doses. Initial pharmacokinetic studies were followed by studies of safety and efficiency involving Technosphere formulations of different therapeutic proteins.

Leadership

Mann was chief executive officer until January 12, 2015 when Hakan Edstrom became CEO and Mann transitioned to executive chairman.

In November 2015, Hakan Edstrom stepped down as CEO and president. Company founder Alfred Mann stepped in as interim CEO on November 19, 2015. In 2016, Matthew Pfeffer was appointed CEO of MannKind, and served as both CEO and CFO. In May 2017, Michael Castagna was named CEO of the company.

Facilities

MannKind has a large corporate office in Westlake Village, California. The Afrezza manufacturing facility is in Danbury, Connecticut. In 2022, the company moved its official headquarters to Danbury.

Ler mais Mostrar menos

Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗

Wikidata ↗

setorHealthcare indústriaBiotechnology funcionários591 paísUS

Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS

06

Receita$349M

2016-12-31 → 2025-12-31

EPS$0.02

2016-12-31 → 2025-12-31

Fluxo de caixa livre$14M

2018-12-31 → 2025-12-31

Margem líquida-11.1%

2017-12-31 → 2025-12-31

Avaliação e Proporções 07–12

Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?

Métrica	MNKD	média 5A	Mediana de Pares	Veredito
P/E (TTM)	-29.2média 5A ≈45.5	≈45.5	·	·
P/S (TTM)	3.0média 5A ≈9.1	≈9.1	21.2	Subvalorizado
P/B (MRQ)	-17.5média 5A ≈-14.7	≈-14.7	·	·
Preço / FCF (TTM)	-64.9média 5A ≈7.7	≈7.7	·	·
Preço / Fluxo de Caixa (TTM)	-146.2média 5A ≈27.0	≈27.0	·	·
Preço / Valor Patrimonial Tangível (MRQ)	-16.3	·	·	·

A mediana dos pares é calculada em uma base padronizada por métrica e pode não corresponder sempre à base TTM/MRQ mostrada para esta ação.

Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC

Métrica	MNKD	média 5A	Mediana de Pares	Veredito
Margem Operacional (TTM)	2.3%média 5A ≈-17.1%	≈-17.1%	-308.7%	Primeira linha
EBITDA Margin (Margem EBITDA)	11.1%média 5A ≈-17.1%	≈-17.1%	-308.7%	Primeira linha
Margem de Impostos Pré-Tributação (TTM)	-12.4%média 5A ≈-37.8%	≈-37.8%	·	·
Margem de Lucro Líquido (TTM)	-11.1%média 5A ≈-37.9%	≈-37.9%	-214.0%	Primeira linha
ROA (TTM)	-7.6%média 5A ≈-12.4%	≈-12.4%	-44.4%	Primeira linha
ROE (TTM)	71.4%média 5A ≈10.3%	≈10.3%	-11.7%	Em linha
ROIC	-316.9%média 5A ≈-71.2%	≈-71.2%	-128.0%	Fraco

Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial

Métrica	Tendência de 5 anos	MNKD	média 5A	Mediana de Pares	Veredito
Índice de liquidez corrente (MRQ)		1.7média 5A ≈3.3	≈3.3	10.6	Baixa liquidez
Índice de Liquidez Seca (MRQ)		1.1média 5A ≈2.8	≈2.8	5.1	Baixa liquidez

Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos

Métrica	MNKD	média 5A	Mediana de Pares	Veredito
Revenue YoY (Receita Ano a Ano)	22.2%média 5A ≈42.6%	≈42.6%	·	·
Revenue CAGR 3Y (CAGR Receita 3A)	51.8%média 5A ≈50.9%	≈50.9%	·	·
Revenue CAGR 5Y (CAGR Receita 5A)	39.9%	·	·	·
EPS YoY	-80.0%	·	·	·
Net Income YoY (Lucro Líquido Ano a Ano)	-78.8%	·	·	·

Métricas por Ação EPS, valor patrimonial por ação, fluxo de caixa por ação, dividendo por ação

Métrica	MNKD	média 5A	Mediana de Pares	Veredito
EPS (Diluted) (EPS (Diluído))	$0.02média 5A ≈$-0.12	≈$-0.12	·	·
Revenue / Share (Receita / Ação)	$1.11média 5A ≈$0.81	≈$0.81	·	·
Cash Flow / Share (Fluxo de Caixa / Ação)	$0.06média 5A ≈$0.01	≈$0.01	·	·
Cash / Share (Caixa / Ação)	$0.24média 5A ≈$0.41	≈$0.41	·	·

Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber

Métrica	MNKD	média 5A	Mediana de Pares	Veredito
Asset Turnover (Giro do Ativo)	0.6média 5A ≈0.5	≈0.5	0.3	Primeira linha
Inventory Turnover (Giro de Estoque)	0.8média 5A ≈1.2	≈1.2	·	·
Receivables Turnover (Giro de Contas a Receber)	13.9média 5A ≈14.7	≈14.7	·	·
Revenue / Employee (Receita anual ÷ funcionários (número de funcionários reportado, yfinance). Derivado — não é um conceito SEC-XBRL armazenado.)	≈$590.5K	·	·	·

valor · ≈ média 5A · mediana do setor · veredicto relativo à mediana

Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados

14

Surpresa Média -86.3%

Próximo relatório Nov 03, 2026

Período	Relatório	EPS Actual	EPS est.	Surpresa
30 de Junho de 2026	Ago 12, 2026	$-0.06	$-0.00	—
31 de Março de 2026	Mai 13, 2026	$-0.05	$-0.00	—
31 de Dezembro de 2025		$-0.05	$0.01	-440.1%
30 de Setembro de 2025		$0.07	$0.02	205.9%
30 de Junho de 2025		$0.00	$0.05	-100.0%
31 de Março de 2025		$0.04	$0.04	-10.9%

Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa

15

Demonstração de Resultados 16

Métrica	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	$349M	$286M	$199M	$100M	$75M	$65M	$63M	$28M	$12M	$175M	$0	$0
Cost of Revenue	$27M	$17M	$21M	$16M	$17M	$15M	$20M	$19M	$17M	$17M	$65M	·
SG&A Expense	$144M	$94M	$94M	$91M	$32M	$25M	$75M	$80M	$75M	$47M	$41M	$79M
Operating Expenses	$88M	$77M	$63M	$57M	$39M	$25M	$108M	$104M	$120M	$107M	$345M	$180M
Operating Income	$39M	$73M	$9M	$-64M	$-47M	$-48M	$-45M	$-77M	$-108M	$67M	$-345M	$-180M
Interest Expense	·	·	$15M	$15M	$15M	·	·	·	·	·	$24M	$20M
Interest Income	$8M	$13M	$6M	$3M	$112.0K	$167.0K	$997.0K	$501.0K	$293.0K	$85.0K	$18.0K	$9.0K
Other Non-op	$-1M	$32.0K	$122.0K	$-102.0K	$-239.0K	$23.0K	$-926.0K	$-437.0K	$13.0K	$-597.0K	$1M	$2M
Pretax Income	$1M	$31M	$-10M	$-87M	$-81M	$-57M	$-52M	$-87M	$-117M	$126M	$-368M	$-198M
Income Tax	$-4M	$3M	$2M	$0	$0	$-218.0K	$0	$240.0K	$51.0K	$0	$0	$0
Net Income	$6M	$28M	$-12M	$-87M	$-81M	$-57M	$-52M	$-87M	$-117M	$126M	$-368M	$-198M
EPS (Basic)	$0.02	$0.10	$-0.04	$-0.34	$-0.32	$-0.26	·	$-0.60	$-1.13	$1.37	$-4.54	$-2.57
EPS (Diluted)	$0.02	$0.10	$-0.04	$-0.34	$-0.32	$-0.26	·	$-0.60	$-1.13	$1.36	$-4.54	$-2.57
Shares (Basic)	305,639,000	274,415,000	267,014,000	257,092,000	249,244,000	222,585,000	·	144,136,000	104,245,000	92,053,000	81,233,000	77,045,000
Shares (Diluted)	314,112,000	283,844,000	267,014,000	257,092,000	249,244,000	222,585,000	·	144,136,000	104,245,000	92,085,000	81,233,000	77,045,000
EBITDA	$39M	$73M	$9M	$-64M	$-47M	$-48M	$-45M	$-77M	$-106M	·	$-334M	$-170M

Balanço Patrimonial 28

Métrica	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Cash & Equivalents	$75M	$46M	$238M	$70M	$124M	$67M	$30M	$71M	$44M	$23M	$59M	$121M
Short-term Investments	$96M	$151M	$57M	$101M	$80M	$0	$20M	·	·	·	·	·
Receivables	$38M	$12M	$15M	$17M	$5M	$4M	$4M	$4M	$3M	$302.0K	$23.0K	$50M
Inventory	$35M	$28M	$29M	$22M	$7M	$5M	$4M	$4M	$3M	$2M	·	$10M
Prepaid Expense	$47M	$31M	$35M	$25M	$3M	$3M	$3M	$3M	$3M	$4M	$4M	$20M
Current Assets	$292M	$268M	$373M	$235M	$219M	$79M	$61M	$82M	$57M	$77M	$77M	$201M
PP&E (Net)	$82M	$85M	$84M	$45M	$37M	$26M	$27M	$26M	$27M	$29M	$49M	$192M
PP&E (Gross)	$196M	$192M	$186M	$144M	$134M	$123M	$122M	$126M	$128M	$129M	$168M	$310M
Accum. Depreciation	$114M	$107M	$102M	$99M	$98M	$97M	$95M	$100M	$101M	$100M	$120M	$118M
Goodwill	$68M	$2M	$2M	$2M	·	·	·	·	·	·	·	·
Intangibles	$5M	$5M	$1M	$1M	·	·	·	·	·	·	·	·
Other Non-current Assets	$20M	$27M	$7M	$10M	$8M	$3M	$6M	$249.0K	$437.0K	$648.0K	$1M	$848.0K
Total Assets	$792M	$394M	$475M	$295M	$321M	$109M	$94M	$108M	$85M	$107M	$126M	$394M
Accounts Payable	$9M	$7M	$10M	$11M	$7M	$6M	$5M	$5M	$7M	$3M	$16M	$7M
Accrued Liabilities	$65M	$40M	$42M	$36M	$27M	$20M	$16M	$15M	$12M	$8M	$8M	$26M
Short-term Debt	·	·	·	·	·	·	$5M	·	·	·	·	·
Current Liabilities	$171M	$82M	$104M	$67M	$48M	$74M	$66M	$75M	$88M	$92M	$268M	$403M
Capital Leases	$11M	$12M	$4M	$5M	$1M	$1M	$3M	·	·	·	·	·
Other Non-current Liabilities	·	·	·	·	$5M	·	·	·	·	·	$15M	$12M
Total Liabilities	$843M	$473M	$721M	$546M	$531M	$289M	$284M	$283M	$299M	$291M	$477M	$468M
Long-term Debt	$355M	$36M	$269M	$273M	$281M	$122M	$119M	$102M	$157M	·	·	·
Total Debt	·	·	·	·	·	·	$5M	·	·	·	·	·
Common Stock	$3M	$3M	$3M	$3M	$3M	$2M	$2M	$2M	$1M	$957.0K	$4M	$4M
Retained Earnings	$-3.20B	$-3.20B	$-3.23B	$-3.22B	$-3.13B	$-3.05B	$-2.99B	$-2.94B	$-2.85B	$-2.74B	$-2.86B	$-2.49B
AOCI	$115.0K	$1M	·	·	·	·	$-19.0K	$-19.0K	$-18.0K	$-24.0K	$-20.0K	$-14.0K
Stockholders' Equity	$-51M	$-79M	$-246M	$-251M	$-209M	$-180M	$-191M	$-175M	$-215M	$-184M	$-350M	$-74M
Liabilities + Equity	$792M	$394M	$475M	$295M	$321M	$109M	$94M	$108M	$85M	$107M	$126M	$394M
Shares Outstanding	307,832,587	302,959,782	270,034,495	263,793,305	251,477,562	242,117,089	211,787,573	187,029,967	119,053,414	95,680,831	85,734,188	406,059,089

Fluxo de Caixa 18

Métrica	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
D&A	$12M	$7M	$5M	$3M	$2M	$2M	$972.0K	$3M	$2M	$2M	$11M	$10M
Stock-based Comp	$24M	$21M	$18M	$13M	$12M	$7M	$6M	$7M	$5M	$5M	$9M	$49M
Deferred Tax	$-19M	$4M	$7M	$-10M	$-20M	$-5M	$-5M	$-11M	$-260M	$48M	$-80M	$-66M
Amort. of Intangibles	$4M	·	·	·	·	·	·	·	·	·	·	·
Restructuring	·	·	·	·	·	·	·	·	·	$2M	$6M	$2M
Other Non-cash	·	·	·	·	·	·	·	·	$306M	·	$291M	$144M
Operating Cash Flow	$18M	$43M	$34M	$-81M	$-62M	$-28M	$-88M	$-38M	$-65M	$-78M	$-57M	$4M
CapEx	$5M	$10M	$42M	$8M	$11M	$801.0K	$3M	$354.0K	·	$1M	$10M	$24M
Investing Cash Flow	$-305M	$-97M	$-2M	$5M	$-152M	$15M	$-23M	$-234.0K	$17M	$-1M	·	·
Debt Issued	·	·	·	·	·	$5M	·	·	·	·	·	$20M
Net Debt Issued	·	·	·	·	·	$5M	·	·	·	·	·	·
Stock Issued	·	·	·	·	·	·	·	·	$564.0K	$893.0K	$28M	·
Net Stock Activity	·	·	·	·	·	·	·	·	$564.0K	·	$28M	·
Financing Cash Flow	$315M	$-137M	$137M	$21M	$270M	$50M	$70M	$61M	$74M	$43M	·	·
Net Change in Cash	$29M	$-191M	$169M	$-54M	$57M	$37M	$-41M	$23M	$25M	$-36M	$-62M	$50M
Taxes Paid	$2M	$4M	·	·	·	·	·	·	·	·	·	·
Free Cash Flow	$14M	$33M	$-8M	$-88M	$-73M	$-29M	$-91M	$-38M	·	·	$-68M	$-20M
Levered FCF	·	·	$-26M	$-98M	·	·	·	·	·	·	$-92M	·

Lucratividade 7

Métrica	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Operating Margin	11.1%	25.4%	4.4%	-64.3%	-62.3%	-73.6%	-70.8%	-274.9%	-921.1%	·	·	·
Net Margin	1.7%	9.7%	-6.0%	-87.6%	-107.3%	-87.9%	-82.3%	-312.2%	-999.0%	·	·	·
Pretax Margin	0.40%	10.7%	-5.2%	-87.6%	-107.3%	-88.2%	-82.3%	-311.3%	-998.6%	·	·	·
EBITDA Margin	11.1%	25.4%	4.4%	-64.3%	-62.3%	-73.6%	-70.8%	-274.9%	-905.8%	·	·	·
ROA	0.99%	6.3%	-3.1%	-28.4%	-37.7%	-56.6%	-51.5%	-90.5%	-122.4%	·	-141.5%	-60.8%
ROE	-11.1%	-19.1%	4.8%	35.8%	41.1%	31.2%	27.7%	45.7%	58.9%	·	173.8%	379.7%
ROIC	-316.9%	-83.2%	-4.1%	25.6%	22.5%	26.5%	24.0%	43.9%	50.4%	·	98.4%	·

Liquidez e Solvência 4

Métrica	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Current Ratio	1.7	3.3	3.6	3.5	4.5	1.1	0.9	1.1	0.7	·	0.3	0.5
Quick Ratio	1.2	2.6	3.0	2.8	4.3	1.0	0.8	1.0	0.5	·	0.2	0.4
Debt / Equity	·	·	·	·	·	·	-0.0	·	·	·	·	·
Interest Coverage	·	·	0.6	-6.7	·	·	·	·	·	·	-14.3	-8.8

Eficiência 3

Métrica	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Asset Turnover	0.6	0.7	0.5	0.3	0.4	0.6	0.6	0.3	0.1	·	0.0	·
Inventory Turnover	0.8	0.6	0.8	1.1	2.8	3.3	5.2	6.2	6.9	·	·	·
Receivables Turnover	13.9	21.4	12.6	9.3	16.4	16.9	16.7	8.2	7.6	·	0.0	·

Por Ação 5

Métrica	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Book Value / Share	$-0.17	$-0.26	$-0.91	$-0.95	$-0.83	$-0.75	$-0.90	$-0.94	$-1.80	·	$-0.82	$-0.18
Revenue / Share	$1.11	$1.01	$0.75	$0.39	·	·	·	$0.19	$0.11	·	·	·
Cash Flow / Share	$0.06	$0.15	$0.13	$-0.31	·	·	·	$-0.26	$-0.62	·	·	·
Cash / Share	$0.24	$0.15	$0.88	$0.26	$0.49	$0.28	$0.14	$0.38	$0.37	·	$0.14	$0.30
EPS (TTM)	$0.02	$0.10	$-0.04	$-0.34	$-0.32	$-0.26	$-0.63	$-0.60	$-1.13	$1.36	$-4.54	$-2.57

Taxas de Crescimento 5

Métrica	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue YoY	22.2%	43.5%	99.4%	32.2%	15.8%	·	·	·	·	·	·	·
Revenue CAGR 3Y	51.8%	55.8%	45.1%	·	·	·	·	·	·	·	·	·
Revenue CAGR 5Y	39.9%	·	·	·	·	·	·	·	·	·	·	·
EPS YoY	-80.0%	·	·	·	·	·	·	·	·	·	·	·
Net Income YoY	-78.8%	·	·	·	·	·	·	·	·	·	·	·

Avaliação (TTM) 13

Métrica	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue TTM	$349M	$286M	$199M	$100M	$75M	$65M	$63M	$28M	$12M	$175M	$0	$0
Net Income TTM	$6M	$28M	$-12M	$-87M	$-81M	$-57M	$-52M	$-87M	$-117M	$126M	$-368M	$-198M
Market Cap	$1.75B	$1.95B	$983M	$1.39B	$1.10B	$758M	$273M	$198M	$276M	·	$3.11B	$10.60B
Enterprise Value	·	·	·	·	·	·	$228M	·	·	·	·	·
P/E	283.5	64.3	-91.0	-15.5	-13.7	-12.0	-2.0	-1.8	-2.1	2.4	-1.6	-10.2
P/S	5.0	6.8	4.9	13.9	14.6	11.6	4.3	7.1	23.5	·	·	·
P/B	-34.2	-24.7	-4.0	-5.5	-5.2	-4.2	-1.4	-1.1	-1.3	·	-8.9	-143.7
P / Cash Flow	95.6	45.8	28.8	-17.2	-17.8	-26.9	-3.1	-5.3	-4.3	·	-54.3	2593.8
P / FCF	127.5	59.4	-117.8	-15.7	-15.0	-26.2	-3.0	-5.2	·	·	-46.0	-529.6
EV / EBITDA	·	·	·	·	·	·	-5.1	·	·	·	·	·
EV / FCF	·	·	·	·	·	·	-2.5	·	·	·	·	·
EV / Revenue	·	·	·	·	·	·	3.6	·	·	·	·	·
Earnings Yield	0.35%	1.6%	-1.1%	-6.5%	-7.3%	-8.3%	-48.8%	-56.6%	-48.7%	42.5%	-62.6%	-9.8%

Demonstração de Resultados 16

Métrica	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Revenue	$109M	$90M	$112M	$82M	$77M	$78M	$77M	$70M	$72M	$66M	$58M	$51M	$49M	$41M	$36M	$33M
Cost of Revenue	$14M	$8M	$14M	$4M	$5M	$4M	$5M	$3M	$6M	$4M	$6M	$4M	$5M	$6M	$4M	$5M
SG&A Expense	$58M	$54M	$58M	$29M	$32M	$25M	$24M	$24M	$24M	$22M	$61M	$11M	$12M	$11M	$64M	$9M
Operating Expenses	$30M	$92M	$-103M	$63M	$21M	$56M	$-86M	$57M	$56M	$50M	$18M	$14M	$14M	$16M	$16M	$17M
Operating Income	$-350.0K	$-2M	$-8M	$19M	$5M	$22M	$26M	$13M	$17M	$17M	$8M	$5M	$2M	$-6M	$-13M	$-10M
Interest Expense	·	·	·	·	·	·	·	·	$6M	$3M	·	$3M	$7M	$3M	·	$3M
Interest Income	$1M	$1M	$2M	$3M	$2M	$2M	$3M	$3M	$3M	$3M	$2M	$2M	$2M	$1M	$957.0K	$663.0K
Other Non-op	$-5M	$-3M	$23M	$-11M	$-4M	$-9M	$24M	$110.0K	$-18M	$-6M	$-164.0K	$318.0K	$-143.0K	$111.0K	$105.0K	$-207.0K
Pretax Income	$-19M	$-16M	$-21M	$8M	$940.0K	$14M	$8M	$13M	$-2M	$11M	$3M	$2M	$-5M	$-10M	$-18M	$-14M
Income Tax	$-106.0K	$253.0K	$-5M	$-204.0K	$272.0K	$459.0K	$1M	$1M	$323.0K	$264.0K	$2M	$0	$0	$0	·	$0
Net Income	$-19M	$-17M	$-16M	$8M	$668.0K	$13M	$7M	$12M	$-2M	$11M	$1M	$2M	$-5M	$-10M	$-18M	$-14M
EPS (Basic)	$-0.06	$-0.05	$-0.05	$0.03	$0.00	$0.04	$0.03	$0.04	$-0.01	$0.04	$0.01	$0.01	$-0.02	$-0.04	$-0.07	$-0.06
EPS (Diluted)	$-0.06	$-0.05	$-0.05	$0.03	$0.00	$0.04	$0.03	$0.04	$-0.01	$0.04	$0.01	$0.01	$-0.02	$-0.04	$-0.07	$-0.06
Shares (Basic)	309,191,000	308,267,000	·	306,806,000	304,954,000	303,481,000	·	274,998,000	273,056,000	270,356,000	·	268,732,000	265,626,000	263,969,000	·	259,300,000
Shares (Diluted)	309,191,000	308,267,000	·	311,638,000	311,484,000	320,897,000	·	284,693,000	273,056,000	324,733,000	·	323,770,000	265,626,000	263,969,000	·	259,300,000
EBITDA	·	$-2M	·	$19M	$5M	$22M	·	$13M	$17M	$17M	·	$5M	$2M	$-6M	·	$-10M

Balanço Patrimonial 25

Métrica	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Cash & Equivalents	$53M	$53M	$75M	$127M	$57M	$47M	$46M	$62M	$97M	$193M	·	$83M	$86M	$86M	·	$54M
Short-term Investments	$58M	$81M	$96M	$133M	$122M	$134M	$151M	$189M	$151M	$107M	·	$58M	$58M	$80M	·	$111M
Receivables	$43M	$28M	$38M	$17M	$27M	$29M	$12M	$18M	$23M	$20M	·	$22M	$28M	$20M	·	$23M
Inventory	$44M	$49M	$35M	$27M	$28M	$29M	$28M	$27M	$25M	$26M	·	$27M	$25M	$22M	·	$18M
Prepaid Expense	$47M	$40M	$47M	$54M	$44M	$34M	$31M	$31M	$30M	$36M	·	$36M	$33M	$15M	·	$12M
Current Assets	$246M	$251M	$292M	$359M	$279M	$274M	$268M	$328M	$326M	$383M	·	$226M	$230M	$223M	·	$218M
PP&E (Net)	$85M	$83M	$82M	$83M	$83M	$84M	$85M	$85M	$85M	$84M	·	$80M	$70M	$55M	·	$41M
PP&E (Gross)	$203M	$198M	$196M	$195M	$194M	$192M	$192M	$192M	$190M	$186M	·	$182M	$170M	$154M	·	$140M
Accum. Depreciation	$118M	$116M	$114M	$113M	$111M	$109M	$107M	$107M	$105M	$103M	·	$101M	$100M	$100M	·	$99M
Goodwill	$68M	$68M	$68M	$2M	$2M	$2M	$2M	$2M	$2M	$2M	·	$2M	$2M	$2M	·	$3M
Intangibles	$5M	$5M	$5M	$5M	$5M	$5M	$5M	$5M	$1M	$1M	·	$1M	$1M	$1M	·	$1M
Other Non-current Assets	$17M	$22M	$20M	$19M	$20M	$28M	$27M	$26M	$16M	$7M	·	$8M	$8M	$16M	·	$17M
Total Assets	$732M	$744M	$792M	$495M	$412M	$410M	$394M	$464M	$444M	$481M	·	$320M	$313M	$298M	·	$294M
Accounts Payable	$11M	$16M	$9M	$7M	$10M	$5M	$7M	$6M	$10M	$7M	·	$17M	$17M	$14M	·	$10M
Accrued Liabilities	$61M	$59M	$65M	$31M	$31M	$40M	$40M	$37M	$41M	$42M	·	$32M	$37M	$33M	·	$30M
Current Liabilities	$143M	$135M	$171M	$109M	$112M	$116M	$82M	$72M	$80M	$100M	·	$96M	$97M	$82M	·	$60M
Capital Leases	$10M	$10M	$11M	$10M	$11M	$11M	$12M	$12M	$3M	$4M	·	$4M	$5M	$5M	·	$6M
Total Liabilities	$800M	$804M	$843M	$539M	$467M	$469M	$473M	$674M	$670M	$711M	·	$572M	$574M	$554M	·	$532M
Long-term Debt	$319M	$319M	$355M	$110M	$36M	$36M	$36M	$228M	$228M	$264M	·	$273M	$274M	$274M	·	$273M
Common Stock	$3M	$3M	$3M	$3M	$3M	$3M	$3M	$3M	$3M	$3M	·	$3M	$3M	$3M	·	$3M
Retained Earnings	$-3.23B	$-3.21B	$-3.20B	$-3.18B	$-3.19B	$-3.19B	$-3.20B	$-3.21B	$-3.22B	$-3.22B	·	$-3.23B	$-3.23B	$-3.23B	·	$-3.20B
AOCI	$-19.0K	$-4.0K	$115.0K	$137.0K	$1M	$1M	$1M	$588.0K	·	·	·	$443.0K	$443.0K	·	·	$-1M
Stockholders' Equity	$-67M	$-59M	$-51M	$-45M	$-55M	$-59M	$-79M	$-210M	$-226M	$-230M	$-246M	$-252M	$-260M	$-255M	$-251M	$-238M
Liabilities + Equity	$732M	$744M	$792M	$495M	$412M	$410M	$394M	$464M	$444M	$481M	·	$320M	$313M	$298M	·	$294M
Shares Outstanding	309,911,682	308,907,331	307,832,587	307,027,189	306,332,133	303,918,969	302,959,782	275,775,038	274,467,247	270,801,781	·	269,543,539	268,235,145	264,278,760	·	263,156,165

Fluxo de Caixa 11

Métrica	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
D&A	$6M	$6M	$6M	$2M	$2M	$2M	$2M	$2M	$2M	$1M	$1M	$1M	$1M	$1M	$1M	$-427.0K
Stock-based Comp	$10M	$6M	$7M	$4M	$8M	$5M	$6M	$5M	$6M	$4M	$4M	$5M	$6M	$4M	$3M	$4M
Amort. of Intangibles	$4M	$4M	·	·	·	·	·	·	·	·	·	·	·	·	·	·
Operating Cash Flow	$-18M	$-5M	$-8M	$24M	$9M	$-6M	$23M	$9M	$4M	$7M	$22M	$9M	$3M	$1M	$-2M	$-28M
CapEx	$5M	$2M	$2M	$1M	$1M	$330.0K	$3M	$1M	$3M	$2M	$6M	$11M	$17M	$8M	$5M	$271.0K
Investing Cash Flow	$18M	$19M	$-292M	$-25M	$6M	$6M	$48M	$-41M	$-55M	$-48M	$-8M	$-12M	$4M	$14M	$15M	$27M
Financing Cash Flow	$559.0K	$-35M	$247M	$72M	$-6M	$1M	$-87M	$-2M	$-45M	$-3M	$142M	$-283.0K	$-6M	$1M	$3M	$20M
Net Change in Cash	$97.0K	$-22M	$-53M	$70M	$10M	$975.0K	$-16M	$-34M	$-96M	$-45M	$155M	$-3M	$315.0K	$16M	$15M	$19M
Taxes Paid	$753.0K	$63.0K	$549.0K	$80.0K	$869.0K	$207.0K	$2M	$236.0K	·	·	·	·	·	·	·	·
Free Cash Flow	·	$-7M	·	·	·	$-7M	·	·	·	$4M	·	·	·	$-7M	·	·
Levered FCF	·	·	·	·	·	·	·	·	·	$2M	·	·	·	$-10M	·	·

Lucratividade 7

Métrica	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Operating Margin	·	-1.8%	·	23.0%	6.9%	28.4%	·	18.2%	22.9%	25.2%	·	9.9%	3.5%	-14.8%	·	-29.3%
Net Margin	·	-18.4%	·	9.7%	0.87%	16.8%	·	16.5%	-2.8%	16.0%	·	3.4%	-10.8%	-24.1%	·	-44.0%
Pretax Margin	·	-18.1%	·	9.5%	1.2%	17.4%	·	18.4%	-2.3%	16.4%	·	3.4%	-10.8%	-24.1%	·	-44.0%
EBITDA Margin	·	-1.8%	·	23.0%	6.9%	28.4%	·	18.2%	22.9%	25.2%	·	9.9%	3.5%	-14.8%	·	-29.3%
ROA	·	-2.9%	·	1.7%	0.16%	2.9%	·	2.9%	-0.53%	2.7%	·	0.56%	-1.8%	-3.2%	·	-5.4%
ROE	·	28.2%	·	-6.3%	-0.48%	-9.1%	·	-5.0%	0.83%	-4.4%	·	-0.70%	2.1%	4.0%	·	6.8%
ROIC	·	2.9%	·	-43.5%	-6.8%	-36.8%	·	-5.5%	-8.8%	-7.1%	·	-2.0%	-0.66%	2.4%	·	·

Liquidez e Solvência 3

Métrica	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Current Ratio	·	1.9	·	3.3	2.5	2.4	·	4.5	4.1	3.8	·	2.3	2.4	2.7	·	3.7
Quick Ratio	·	1.2	·	2.5	1.8	1.8	·	3.7	3.4	3.2	·	1.7	1.8	2.3	·	3.2
Interest Coverage	·	·	·	·	·	·	·	·	2.7	6.5	·	1.8	0.3	-2.5	·	·

Eficiência 3

Métrica	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Asset Turnover	·	0.2	·	0.2	0.2	0.2	·	0.2	0.2	0.2	·	0.2	0.2	0.1	·	0.1
Inventory Turnover	·	0.2	·	0.2	0.2	0.1	·	0.1	0.2	0.2	·	0.2	0.2	0.4	·	0.4
Receivables Turnover	·	3.2	·	4.6	3.0	3.2	·	3.5	2.8	3.3	·	2.3	2.3	2.8	·	2.0

Por Ação 5

Métrica	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Book Value / Share	·	$-0.19	·	$-0.15	$-0.18	$-0.19	·	$-0.76	$-0.82	$-0.85	·	$-0.93	$-0.97	$-0.97	·	$-0.90
Revenue / Share	·	$0.29	·	$0.26	$0.25	$0.24	·	$0.25	$0.27	$0.20	·	$0.16	$0.18	$0.15	·	$0.13
Cash Flow / Share	·	$-0.02	·	·	·	$-0.02	·	·	·	$0.02	·	·	·	$0.00	·	·
Cash / Share	·	$0.17	·	$0.41	$0.19	$0.16	·	$0.23	$0.35	$0.71	·	$0.31	$0.32	$0.32	·	$0.21
EPS (TTM)	$-0.08	$-0.07	·	$0.10	$0.11	$0.10	·	$0.08	$0.05	$0.04	·	$-0.12	$-0.19	$-0.28	·	$-0.38

Avaliação (TTM) 8

Métrica	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Revenue TTM	$358M	$361M	·	$314M	$302M	$298M	·	$267M	$248M	$225M	·	$177M	$158M	$128M	·	$76M
Net Income TTM	$-27M	$-24M	·	$29M	$33M	$30M	·	$22M	$12M	$8M	·	$-31M	$-47M	$-71M	·	$-98M
Market Cap	·	$757M	·	$1.65B	$1.15B	$1.53B	·	$1.73B	$1.43B	$1.23B	·	$1.11B	$1.09B	$1.08B	·	$813M
P/E	-53.2	-35.0	·	53.7	34.0	50.3	·	78.6	104.4	113.2	·	-34.4	-21.4	-14.6	·	-8.1
P/S	·	2.1	·	5.3	3.8	5.1	·	6.5	5.8	5.5	·	6.3	6.9	8.4	·	10.7
P/B	·	-12.8	·	-37.0	-20.8	-26.1	·	-8.3	-6.3	-5.3	·	-4.4	-4.2	-4.2	·	-3.4
P / Cash Flow	·	-141.1	·	·	·	-239.7	·	·	·	183.0	·	·	·	937.3	·	·
Earnings Yield	-1.9%	-2.9%	·	1.9%	2.9%	2.0%	·	1.3%	0.96%	0.88%	·	-2.9%	-4.7%	-6.8%	·	-12.3%

Período mais recente à esquerda · valores nulos mostrados como ·

Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos

16

Métrica	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Receita	$349M	$286M	$199M	$100M	$75M
Margem Operacional %	11.1%	25.4%	4.4%	-64.3%	-62.3%
Lucro líquido	$6M	$28M	$-12M	$-87M	$-81M
EPS Diluído	$0.02	$0.10	$-0.04	$-0.34	$-0.32

Métrica	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Índice de liquidez corrente	1.7	3.3	3.6	3.5	4.5
Índice de Liquidez Seca	1.2	2.6	3.0	2.8	4.3

Métrica	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Fluxo de caixa livre	$14M	$33M	$-8M	$-88M	$-73M

Investidores institucionais (13F) 271 declarantes · $883.4M total · Em 30 de Setembro de 2026

17

Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.

Detentores 271

Valor detido $883.4M

Novas posições 51

Posições encerradas 39

Atividade institucional — Q2 2026 vs trimestre anterior

Novas posições	Posições encerradas	Aumentou	Diminuído	Variação líquida de ações
51 (0 vs trimestre anterior)	39 (-8 vs trimestre anterior)	98 (+12 vs trimestre anterior)	63 (-7 vs trimestre anterior)	+1.9M

Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.

Instituição	Valor	Ações	% de 13F rastreado	Tipo
BlackRock, Inc.	$136.887.530	32.133.223	15,50%	Ações
VANGUARD GROUP INC	$101.384.549	17.880.873	11,48%	Ações
Rubric Capital Management LP	$76.680.000	18.000.000	8,68%	Ações
STATE STREET CORP	$68.901.423	16.174.043	7,80%	Ações
VANGUARD CAPITAL MANAGEMENT LLC	$56.101.610	13.169.392	6,35%	Ações
GEODE CAPITAL MANAGEMENT, LLC	$33.861.886	7.947.203	3,83%	Ações
WELLINGTON MANAGEMENT GROUP LLP	$33.418.878	7.844.807	3,78%	Ações
Frazier Life Sciences Management, L.P.	$28.116.000	6.600.000	3,18%	Ações
Deep Track Capital, LP	$25.560.000	6.000.000	2,89%	Ações
180 WEALTH ADVISORS, LLC	$21.126.835	4.959.351	2,39%	Ações
FMR LLC	$17.470.455	4.101.046	1,98%	Ações
TSP Capital Management Group, LLC	$16.923.596	3.972.675	1,92%	Ações
AQR CAPITAL MANAGEMENT LLC	$16.225.589	3.808.824	1,84%	Ações
MORGAN STANLEY	$14.802.946	3.474.870	1,68%	Ações
BRAIDWELL LP	$14.732.908	3.458.429	1,67%	Ações
VANGUARD PORTFOLIO MANAGEMENT LLC	$12.789.240	3.002.169	1,45%	Ações
NORTHERN TRUST CORP	$12.299.856	2.887.290	1,39%	Ações
UBS Group AG	$12.295.344	2.886.231	1,39%	Ações
TWO SIGMA INVESTMENTS, LP	$11.475.213	2.693.712	1,30%	Ações
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	$11.070.577	2.598.727	1,25%	Ações
BANK OF AMERICA CORP /DE/	$10.074.356	2.364.872	1,14%	Ações
VANGUARD FIDUCIARY TRUST CO	$9.358.279	2.196.779	1,06%	Ações
GOLDMAN SACHS GROUP INC	$9.178.165	2.154.499	1,04%	Ações
WELLS FARGO & COMPANY/MN	$6.289.519	1.476.413	0,71%	Ações
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$5.030.221	1.180.803	0,57%	Ações
DIMENSIONAL FUND ADVISORS LP	$4.661.185	1.094.192	0,53%	Ações
Caption Management, LLC	$4.260.000	1.000.000	0,48%	Opção de venda
Bank of New York Mellon Corp	$3.827.454	898.463	0,43%	Ações
CITADEL ADVISORS LLC	$3.818.068	896.260	0,43%	Ações
J. Goldman & Co LP	$3.478.669	816.589	0,39%	Ações
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	$3.019.973	1.232.642	0,34%	Ações
SCOPIA CAPITAL MANAGEMENT LP	$2.960.534	694.961	0,34%	Ações
Balyasny Asset Management L.P.	$2.914.296	684.107	0,33%	Ações
TWO SIGMA ADVISERS, LP	$2.897.166	510.964	0,33%	Ações
VICTORY CAPITAL MANAGEMENT INC	$2.771.407	650.565	0,31%	Ações
Nuveen, LLC	$2.708.218	635.732	0,31%	Ações
Swiss National Bank	$2.502.324	587.400	0,28%	Ações
STATE OF WISCONSIN INVESTMENT BOARD	$2.177.052	511.045	0,25%	Ações
JACOBS LEVY EQUITY MANAGEMENT, INC	$2.106.540	494.493	0,24%	Ações
1492 Capital Management LLC	$2.052.136	481.722	0,23%	Ações
Mariner, LLC	$2.020.189	474.236	0,23%	Ações
MILLENNIUM MANAGEMENT LLC	$1.836.597	431.126	0,21%	Ações
Schonfeld Strategic Advisors LLC	$1.774.216	416.483	0,20%	Ações
Squarepoint Ops LLC	$1.759.644	413.062	0,20%	Ações
Jefferies Financial Group Inc.	$1.694.202	397.700	0,19%	Ações
ExodusPoint Capital Management, LP	$1.666.261	391.141	0,19%	Ações
JANE STREET GROUP, LLC	$1.658.418	389.300	0,19%	Opção de compra
PRINCIPAL FINANCIAL GROUP INC	$1.629.561	382.526	0,18%	Ações
Man Group plc	$1.624.023	381.226	0,18%	Ações
RHUMBLINE ADVISERS	$1.604.647	376.681	0,18%	Ações

Mostrar todos os 271 proprietários institucionais →

Ativistas e proprietários de 5%+ 2 participações

18

Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.

Declarante	Declarado	Participação	Status	Propósito	Declaração
Alfred E. Mann, Alfred E. Mann Living Trust, Biomed Partners, LLC, Minimed Infusion, Inc., The Mann Group LLC ×2 declarações	10 de Julho de 2012	·	Declaração inicial	Investimento passivo	SEC
Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada	31 de Janeiro de 2006	·	Declaração inicial	·	SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Executivos da empresa 43 insiders · 27 diretores · 19 conselheiros

19

Investidor com informação privilegiada	Função	Última atividade	Ações detidas	Compras 12m	Vendas 12m	Líquido 12m
Michael Castagna	Chief Executive Officer	15 de Julho de 2026 M	2.433.779	1	4	$-990.292
Hakan Edstrom	President & CEO	27 de Agosto de 2015 A	1.114.340	0	0	$0
Christopher B Prentiss	Chief Financial Officer	15 de Julho de 2026 F	318.668	0	0	$0
Juergen Martens	Corporate VP and COO	27 de Agosto de 2015 A	106.539	0	0	$0
Dominic Marasco	Pres, Endocrine Business Unit	15 de Julho de 2026 F	343.398	0	0	$0
Sanjay R Singh	EVP Technical Operations	15 de Julho de 2026 M	478.966	0	1	$-94.448
Stuart A Tross	Chief People & Workpl Officer	15 de Julho de 2026 M	1.058.142	0	1	$-297.548
David Thomson	EVP Genl Counsel & Secretary	15 de Julho de 2026 M	797.554	0	3	$-930.755
Ajay Ahuja	Chief Medical Officer	23 de Março de 2026 A	318.200	0	0	$0
Lauren M Sabella	EVP Operations	15 de Julho de 2025 F	349.841	0	0	$0
Burkhard Blank	EVP Chief Medical Officer	15 de Julho de 2025 F	460.791	0	0	$0
Joseph Kocinsky	Chief Technology Officer	27 de Agosto de 2022 F	745.233	0	0	$0
Alejandro Galindo	EVP Endocrine Business Unit	28 de Fevereiro de 2022 A	576.690	0	0	$0
Rosabel Realica Alinaya	VP, IR & Treasury	27 de Agosto de 2020 A	167.119	0	0	$0
David M Kendall	Chief Medical Officer	31 de Julho de 2020 P	41.059	0	0	$0
Patrick Mccauley	Chief Commercial Officer	25 de Fevereiro de 2020 A	83.972	0	0	$0
Courtney Barton	Chief Compl & Privacy Officer	31 de Julho de 2019 P	29.584	0	0	$0
Elizabeth Garrett Ingram	Chief Marketing Officer	14 de Maio de 2019 A	43.012	0	0	$0
Raymond W. Urbanski	Corp VP, CMO	10 de Agosto de 2017 S	2.924	0	0	$0
Linda A Adreveno	Sr. VP, HR	18 de Fevereiro de 2016 A	92.200	0	0	$0
Alfred E Mann	Executive Chairman	22 de Agosto de 2015 F	1.005.990	0	0	$0
Diane Palumbo	Vice President, Human Resource	23 de Fevereiro de 2015 F	50.624	0	0	$0
Peter C Richardson	Chief Scientific Officer	3 de Março de 2012 F	133.611	0	0	$0
Richard L Anderson	Corporate VP	16 de Novembro de 2008 F	204.401	0	0	$0
John R. Riesenberger	VP & Chief Commercial Officer	13 de Agosto de 2008 A	14.650	0	0	$0
Dan Burns	VP & President, MKBP	8 de Dezembro de 2006 A	14.800	0	0	$0
Wendell W Cheatham	VP, Medical & Reg Affairs	19 de Agosto de 2004 A	300	0	0	$0
Steven B. Binder	Conselheiro	25 de Setembro de 2026 S	713.258	0	5	$-683.703
Sabrina Kay	Conselheiro	20 de Maio de 2026 A	265.600	0	0	$0
Jennifer Grancio	Conselheiro	20 de Maio de 2026 A	244.815	0	0	$0
James Samuel Shannon	Conselheiro	20 de Maio de 2026 A	64.635	0	0	$0
Michael A Friedman	Conselheiro	20 de Maio de 2026 A	47.500	0	0	$0
Anthony C Hooper	Conselheiro	20 de Maio de 2026 A	236.153	0	0	$0
Christine Mundkur	Conselheiro	20 de Maio de 2026 A	254.493	0	0	$0
Ronald J Consiglio	Conselheiro	20 de Maio de 2026 A	132.342	0	0	$0
Kent Kresa	Conselheiro	15 de Maio de 2024 A	274.541	0	0	$0
Henry L Nordhoff	Conselheiro	14 de Maio de 2019 A	103.426	0	0	$0
David Maccallum	Conselheiro	16 de Maio de 2018 A	114.790	0	0	$0
Matthew J Pfeffer	Conselheiro	28 de Agosto de 2017 F	81.961	0	0	$0
Abraham E Cohen	Conselheiro	17 de Agosto de 2012 S	56.424	0	0	$0
Heather Hay Murren	Conselheiro	13 de Agosto de 2008 A	10.100	0	0	$0
Kathleen Connell	Conselheiro	25 de Maio de 2006 A	·	0	0	$0
Llew Keltner	Conselheiro	25 de Maio de 2006 A	·	0	0	$0

Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto

Participação em ETFs Detido por 29 ETFs

20

O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.

Fundo	Peso	Unidades	Em	Fonte
JSMD · Janus Detroit Street Trust	0,62%	1.678.187 NS	31 de Julho de 2026	N-PORT
QQQS · Invesco Exchange-Traded Fund Trust …	0,52%	29.891 SH	2 de Outubro de 2026	Diário
JSML · Janus Detroit Street Trust	0,49%	450.643 NS	31 de Julho de 2026	N-PORT
FYC · First Trust Exchange-Traded AlphaDE…	0,37%	1.212.660 NS	31 de Julho de 2026	N-PORT
LABU · Direxion Shares ETF Trust	0,23%	289.432 NS	31 de Julho de 2026	N-PORT
FYX · First Trust Exchange-Traded AlphaDE…	0,12%	409.547 NS	31 de Julho de 2026	N-PORT
IBBQ · Invesco Exchange-Traded Fund Trust …	0,09%	22.737 SH	2 de Outubro de 2026	Diário
IBB · iShares Trust	0,08%	2.264.902 SH	11 de Setembro de 2026	Diário
VTWG · VANGUARD SCOTTSDALE FUNDS	0,08%	330.117 SH	19 de Agosto de 2026	Diário
IWO · iShares Trust	0,08%	2.877.921 SH	11 de Setembro de 2026	Diário
FAD · First Trust Exchange-Traded AlphaDE…	0,07%	109.855 NS	31 de Julho de 2026	N-PORT
PWS · Pacer Funds Trust	0,06%	3.954 NS	31 de Julho de 2026	N-PORT
ESML · iShares Trust	0,05%	333.357 SH	11 de Setembro de 2026	Diário
VTWO · VANGUARD SCOTTSDALE FUNDS	0,04%	1.771.496 SH	19 de Agosto de 2026	Diário
RSSL · Global X Funds	0,04%	147.059 NS	31 de Julho de 2026	N-PORT
ISCG · iShares Trust	0,04%	96.772 SH	11 de Setembro de 2026	Diário
IWM · iShares Trust	0,04%	7.845.946 SH	11 de Setembro de 2026	Diário
VHT · VANGUARD WORLD FUND	0,02%	874.372 SH	19 de Agosto de 2026	Diário
FHLC · FIDELITY COVINGTON TRUST	0,02%	139.696 NS	31 de Julho de 2026	N-PORT
VXF · VANGUARD INDEX FUNDS	0,01%	3.543.398 SH	19 de Agosto de 2026	Diário
WSML · iShares Trust	0,01%	16.637 SH	11 de Setembro de 2026	Diário
TILT · FlexShares Trust	0,00%	23.700 NS	31 de Julho de 2026	N-PORT
ITOT · iShares Trust	0,00%	465.405 SH	11 de Setembro de 2026	Diário
IWV · iShares Trust	0,00%	84.120 SH	10 de Setembro de 2026	Diário
DFAC · Dimensional ETF Trust	0,00%	58.407 NS	31 de Julho de 2026	N-PORT
DFAS · Dimensional ETF Trust	0,00%	11.291 NS	31 de Julho de 2026	N-PORT
VTI · VANGUARD INDEX FUNDS	0,00%	9.327.332 SH	19 de Agosto de 2026	Diário
VTHR · VANGUARD SCOTTSDALE FUNDS	0,00%	26.184 SH	19 de Agosto de 2026	Diário
ISCB · iShares Trust	·	13.557 SH	11 de Setembro de 2026	Diário

MNKD Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta

21

classificação · 14 analistas COMPRA

Alvo mediano $7.50 +97,4%

4 28,6% Compra forte

8 57,1% Compra

2 14,3% Manter

0 0,0% Venda

0 0,0% Venda forte

Preço-alvo de 12 meses

8 analistas · 2026-09-28

Alvo médio $7.97 +109,7%

← Abaixo de todos os alvos Preço atual $3.80

Mín$4.75 Média$7.97 Máx$13.00

Comparação de pares (subindústria GICS) Métricas chave vs pares do setor

22

Base do ano fiscal, preços no fechamento do último ano fiscal de cada empresa.

Ticker	Capitalização de Mercado	P/E	Receita YoY	Margem Líquida	ROE	Margem Bruta
MNKD	$1.75B	283.5	22.2%	1.7%	-11.1%	·
ORIC	$806M	-5.6	·	·	-36.5%	·
DMRA	·	·	38.3%	-17981.1%	-167.0%	·
REPL	$633M	-2.3	·	·	-146.2%	·
TRAX	·	·	·	·	·	·
BCAX	$953M	-6.7	·	·	-33.0%	·
VOR	$506M	-0.2	·	·	83.4%	·
MGTX	$645M	-5.6	144.6%	-140.3%	8062.2%	·
JANX	$833M	-7.5	-5.5%	-1136.2%	-11.7%	·

Últimas notícias Notícias recentes mencionando esta empresa

23

Wells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story” Yahoo Finance · 3 meses, 2 semanas atrás MannKind (MNKD) Advances Clinical Trials for Inhaled IPF Therapy Yahoo Finance · 3 meses, 3 semanas atrás H.C. Wainwright e Wells Fargo elevam as metas de preço da MannKind (MNKD) Yahoo Finance · 4 meses, 2 semanas atrás A MannKind Corporation (MNKD) é uma das ações penny populares na Robinhood para comprar? Yahoo Finance · 6 meses atrás

Sinais de trading Sinais recentes de compra/venda com preço de entrada e relação risco/recompensa

25

BOUNCE_UP Stop out Dez 23

risco 1 recompensa 2,00

entrada $5.89 R:R 2,00

Nenhum sinal aberto no momento — nenhum cartão está preenchido, e isso é honesto.

Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos

26

Escolha as métricas que importam para si — clique no + ao lado de qualquer linha em Fundamentos Completos acima.

Sua seleção é salva e acompanha você em todos os tickers.

MNKD MannKind Corporation - Common Stock